Bubs Australia Limited (BUBSF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 20.07 means the share price is 20.07 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $69.2M is the value of all shares combined. Beta 0.10: the stock has moved about 90% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBubs Australia Limited (BUBSF) trades at $0.0774. Bubs Australia Limited (BUBSF) is an Australian-based infant nutrition company focused on goat milk and organic cow's milk formulas, along with baby food products. Market cap: $69.2M, Sector: Consumer defensive.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BUBSF: BUBSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BUBSF against Consumer Defensive peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BUBSF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Bubs Australia Limited (BUBSF) Consumer Business Overview
Bubs Australia Limited (BUBSF) is a packaged foods company specializing in infant nutrition, particularly goat milk and organic formulas, targeting health-conscious parents in Australia, China, and international markets. With a focus on premium ingredients and specialized products, Bubs aims to capture a niche segment within the competitive baby food industry.
What Is the Investment Thesis for BUBSF?
Bubs Australia Limited presents a focused investment opportunity within the infant nutrition market, driven by its specialization in goat milk-based formulas and organic offerings. With a market capitalization of $69.2M and a P/E ratio of 20.07, Bubs demonstrates potential for growth, supported by a gross margin of 46.2% and a profit margin of 3.5%. Key growth catalysts include expanding its presence in the Chinese market and leveraging its Vita Bubs brand for children's supplements. The company's low beta of 0.10 suggests relatively low volatility. However, investors may want to evaluate the competitive landscape and potential regulatory changes in the infant formula industry as potential risks. The company's ability to maintain and grow its market share in key regions will be crucial for its long-term success.
Based on FMP financials and quantitative analysis
BUBSF Key Highlights
Market capitalization of $69.2M indicates the company's current size and valuation in the market.
- P/E ratio of 20.07 reflects investor expectations for future earnings growth.
- Gross margin of 46.2% demonstrates the company's ability to efficiently manage production costs and maintain pricing power.
- Profit margin of 3.5% shows the percentage of revenue that translates into profit after all expenses.
- Beta of 0.10 suggests the stock is less volatile than the overall market.
Who Are BUBSF's Competitors?
BUBSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CVNZF Comvita Limited | $0.42 | 0.00% | $30.1M | — |
| CWGL Crimson Wine Group, Ltd. | $4.50 | -2.17% | $92.6M | — |
| GBCMY Global Bio-chem Technology Group Company Limited | $4.14 | 0.00% | $7.39M | — |
| MJWNY Naked Wines plc | $3.71 | 0.00% | $62.1M | — |
| NBBTF Natural Beauty Bio-Technology Limited | $0.05 | 0.00% | $100M | — |
| LFVN LifeVantage Corporation | $6.37 | -2.15% | $80.4M | 615-pillar |
| WYHG Wing Yip Food Holdings Group Limited | $4.52 | -9.24% | $56.9M | 499-signal |
| FTLF FitLife Brands, Inc. | $9.22 | -3.05% | $86.6M | 605-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BUBSF's Key Strengths?
Specialization in goat milk-based infant formula.
- Strong brand reputation in the Australian market.
- Growing presence in the Chinese market.
- Focus on organic and natural ingredients.
What Are BUBSF's Weaknesses?
Limited market share compared to larger competitors.
- Reliance on a niche market segment.
- Exposure to regulatory risks in the infant formula industry.
- Relatively small market capitalization.
What Could Drive BUBSF Stock Higher?
Expansion into new international markets, driving revenue growth.
- Product innovation and diversification, attracting new customers.
- Potential strategic partnerships or acquisitions, expanding market reach.
- Strengthening of the Vita Bubs brand, increasing sales of children's supplements.
What Are the Key Risks for BUBSF?
Financial-distress signal — its Altman Z-Score of -1.13 sits in the distress zone (elevated bankruptcy risk).
- Intense competition from established players in the infant nutrition market.
- Regulatory changes and recalls in the infant formula industry.
- Economic downturns and fluctuations in currency exchange rates.
- Dependence on key markets such as Australia and China.
- Supply chain disruptions affecting the availability of raw materials.
What Are the Growth Opportunities for BUBSF?
- Expansion in the Chinese Market: Bubs has a significant opportunity to expand its presence in the Chinese market, where demand for high-quality infant formula is strong. By leveraging its existing distribution channels and marketing efforts, Bubs can increase its market share in this key region. The Chinese infant formula market is projected to reach $30 billion by 2028, providing a substantial growth opportunity for Bubs.
- Product Innovation and Diversification: Bubs can drive growth through continuous product innovation and diversification. This includes developing new formulations, flavors, and formats to meet evolving consumer preferences. The company can also explore expanding its product line to include complementary products such as baby food and snacks. The market for organic baby food is growing at a rate of 10% annually, presenting a significant opportunity for Bubs.
- Strategic Partnerships and Acquisitions: Bubs can pursue strategic partnerships and acquisitions to expand its market reach and product portfolio. Collaborating with established players in the infant nutrition industry can provide access to new distribution channels and technologies. Acquiring complementary businesses can broaden the company's product offerings and strengthen its competitive position. The global market for infant nutrition products is consolidating, creating opportunities for strategic acquisitions.
- Strengthening the Vita Bubs Brand: Bubs can capitalize on the growing demand for children's vitamin and mineral supplements by strengthening its Vita Bubs brand. This includes expanding the product line, increasing marketing efforts, and leveraging the brand's reputation for quality and safety. The children's supplement market is projected to reach $5 billion by 2027, offering a significant growth opportunity for Bubs.
- Geographic Expansion: Bubs can expand its geographic presence beyond Australia and China by targeting other key markets such as Southeast Asia and the Middle East. These regions have a growing demand for high-quality infant formula and offer attractive growth opportunities. By establishing local distribution networks and tailoring its products to meet local preferences, Bubs can successfully penetrate these markets. The Southeast Asian infant formula market is projected to grow at a rate of 8% annually.
What Are BUBSF's Competitive Advantages?
- Brand reputation for quality and safety in the infant nutrition market.
- Specialization in goat milk-based formulas, catering to a niche market.
- Proprietary formulations and manufacturing processes.
- Established distribution channels in key markets such as Australia and China.
What Does BUBSF Do?
Bubs Australia Limited, established in 1993 and headquartered in Frenchs Forest, Australia, is a prominent player in the infant nutrition sector. The company focuses on producing and distributing a range of specialized infant formula and baby food products, with a particular emphasis on goat milk-based options. Bubs caters to infants and toddlers with its organic baby food, goat milk infant formula, organic cow's milk infant formula, and supreme formula. Additionally, it offers adult goat milk powder and fresh dairy products. The company's product line extends to pouches, cereals, porridges, rusks, and snacks, all marketed under the Bubs brand. Recognizing the importance of nutritional supplements for children, Bubs also provides vitamin and mineral supplements under the Vita Bubs brand. Beyond its own branded products, Bubs offers canning services for nutritional dairy products, leveraging its manufacturing capabilities. The company actively protects its intellectual property through trademarks and patents. Bubs has expanded its reach beyond Australia, establishing a presence in China and other international markets, positioning itself to capitalize on the growing demand for high-quality infant nutrition products globally.
What Products and Services Does BUBSF Offer?
- Produces and sells organic baby food products.
- Offers goat milk infant formula.
- Provides organic cow's milk infant formula.
- Manufactures adult goat milk powder.
- Sells fresh dairy products.
- Offers children's vitamin and mineral supplements under the Vita Bubs brand.
- Provides canning services for nutritional dairy products.
- Holds intellectual property and trademarks related to its products.
How Does BUBSF Make Money?
- Develops and manufactures infant nutrition products.
- Markets and distributes products through retail channels and online platforms.
- Generates revenue through the sale of branded products and canning services.
- Focuses on premium ingredients and specialized formulations to differentiate its products.
What Industry Does BUBSF Operate In?
Bubs Australia Limited operates within the competitive packaged foods industry, specifically targeting the infant nutrition segment. The global infant formula market is driven by increasing birth rates in developing countries, rising disposable incomes, and a growing awareness of the importance of infant nutrition. Key competitors include companies like CVNZF (The a2 Milk Company), CWGL (China Mengniu Dairy), GBCMY (Nestle), MJWNY (Danone), and NBBTF (Nutribio). Bubs differentiates itself through its focus on goat milk-based formulas and organic products, catering to a niche market of health-conscious parents seeking premium infant nutrition options.
Who Are BUBSF's Key Customers?
- Parents of infants and toddlers seeking high-quality nutrition.
- Health-conscious consumers looking for organic and natural baby food options.
- Retailers and distributors of infant formula and baby food products.
- Consumers in Australia, China, and other international markets.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 53 |
| 2026-08-26 | 53 |
| 2026-08-29 | 53 |
| 2026-09-01 | 53 |
| 2026-09-04 | 53 |
| 2026-09-07 | 53 |
| 2026-09-10 | 53 |
What changed?
The score has stayed at 53.
Over the same 18 days the stock moved +0.0%.
Forward Outlook
Wall Street analysts project Bubs Australia Limited revenue of about $111.7M for fiscal 2026, with EPS near $-0.00. The estimate reflects 3 contributing analysts.
Financial Health
Bubs Australia Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.13 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Bubs Australia Limited stands at 8.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.5%, showing how much profit it generates from its asset base. BUBSF trades at a trailing price-to-earnings ratio of 20.07, below the Consumer Defensive sector average of ~27.60x. Its free cash flow yield is 0.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.0%, the inverse of the P/E and a quick read on earnings relative to price.
Bubs Australia Limited (BUBSF) Valuation Context
Valued at $69.2M, BUBSF is classified as a micro-cap stock.
BUBSF Revenue & Earnings Trend
In Jun 2026, BUBSF generated $56.3M in top-line revenue, marking a sequential increase of 1.4%. The company recorded a net loss of $6.4M, with diluted EPS of $-0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Consumer Defensive company. Across the four most recent quarters, BUBSF averaged $0.00 in diluted EPS.
Company Profile
Bubs Australia Limited operates in the Packaged Foods industry within the Consumer Defensive sector. It is headquartered in Dandenong, AU. The company is led by CEO Joe Coote. BUBSF has traded publicly since 2022.
BUBSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Specialization in goat milk-based infant formula.
- Strong brand reputation in the Australian market.
- Growing presence in the Chinese market.
- Focus on organic and natural ingredients.
Bear Case
- Limited market share compared to larger competitors.
- Reliance on a niche market segment.
- Exposure to regulatory risks in the infant formula industry.
- Relatively small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Jun 2026 | A$56M | -A$6M | -A$0.01 |
| Dec 2025 | A$55M | A$2M | A$0.0020 |
| Jun 2025 | A$54M | A$2M | A$0.0022 |
| Dec 2024 | A$49M | A$4M | A$0.0040 |
Based on FMP financials and quantitative analysis · Reported in AUD
BUBSF Latest News
-
Bubs Australia Limited (BUBSF) Discusses FDA Authorization Milestone and US Growth Strategy in Infant Formula Market Transcript
seekingalpha.com · Sep 10, 2026
-
Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump
reuters.com · Sep 7, 2026
-
Bubs Australia Limited (BUBSF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Aug 27, 2026
-
3 ASX Penny Stocks With Market Caps Under A$700M
Yahoo! Finance: BUBSF News · Jan 30, 2026
BUBSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BUBSF.
Price Targets
Wall Street price target analysis for BUBSF.
BUBSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BUBSF; grades run from A+ (80-100) to F (below 30).
Latest News
Bubs Australia Limited (BUBSF) Discusses FDA Authorization Milestone and US Growth Strategy in Infant Formula Market Transcript
Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump
Bubs Australia Limited (BUBSF) Q4 2026 Earnings Call Transcript
3 ASX Penny Stocks With Market Caps Under A$700M
Leadership: Joe Coote
Managing Director
Joe Coote is the Managing Director of Bubs Australia Limited, leading the company's strategic direction and operations. His background includes extensive experience in the consumer goods industry, with a focus on sales, marketing, and business development. Prior to joining Bubs, Joe held leadership positions at various multinational companies, where he was responsible for driving revenue growth and expanding market share. He brings a strong understanding of the infant nutrition market and a proven track record of success in building brands and managing teams.
Track Record: Under Joe Coote's leadership, Bubs Australia has focused on expanding its presence in key international markets, particularly China, and has continued to innovate its product offerings to meet evolving consumer needs. He has overseen the launch of new product lines and the strengthening of the company's distribution network. His strategic decisions have contributed to the company's growth in revenue and market share.
BUBSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bubs Australia Limited (BUBSF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be experiencing financial distress, or be subject to regulatory scrutiny. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher price volatility due to lower trading volumes.
- Potential for market manipulation and fraud.
- Increased risk of delisting or regulatory action.
- Limited access to company information and management.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or regulatory actions related to the company.
- Established brand presence in the infant nutrition market.
- Focus on high-quality ingredients and product formulations.
- Presence in international markets such as China.
- Active management team with industry experience.
- Positive customer reviews and testimonials.
BUBSF Consumer Defensive Stock FAQ
Is BUBSF a good stock?
Stock Expert AI does not rate BUBSF buy, sell or hold. Bubs Australia Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BUBSF stock?
Investors should monitor for updates on analyst ratings and price targets as they become available. Key valuation metrics to consider include the company's P/E ratio, gross margin, and profit margin.
What are the key factors to evaluate for BUBSF?
Evaluate BUBSF on fundamentals, analyst consensus, and risk factors. P/E: 20.07x vs the S&P 500's ~20-25x. Key growth catalysts include expanding its presence in the Chinese market and leveraging its Vita Bubs brand for children's supplements. Not financial advice.
How frequently does BUBSF data refresh on this page?
BUBSF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BUBSF's recent stock price performance?
Bubs Australia Limited (BUBSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in goat milk-based infant formula. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BUBSF overvalued or undervalued right now?
Bubs Australia Limited (BUBSF) trades at 20.07x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BUBSF?
Yes, most major brokerages offer fractional shares of Bubs Australia Limited (BUBSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BUBSF's earnings and financial reports?
Bubs Australia Limited (BUBSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BUBSF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- OTC market data may be less reliable than data for major exchanges.